Is Sermorelin Legal in Michigan?

What Sermorelin Is and Why Its Legal Status Matters

Sermorelin is a synthetic 29-amino-acid analog of endogenous growth-hormone-releasing hormone (GHRH). It stimulates the pituitary gland to produce and release endogenous growth hormone rather than delivering exogenous GH directly. The FDA originally approved it as Geref Diagnostic (sermorelin acetate) for stimulation testing of GH secretion. That brand was voluntarily withdrawn from the market in 2008, which is the origin of nearly every legal question patients ask today.

Because the original brand no longer exists, almost all sermorelin dispensed in clinical practice in 2025 comes from compounding pharmacies. Whether that compounded product is legal depends entirely on the pharmacy's compliance with federal and state rules, not on any state-level prohibition specific to sermorelin.

Why the Brand Withdrawal Changed Everything

When Geref was pulled, sermorelin did not disappear from medical practice. Physicians continued prescribing it as a compounded preparation. The withdrawal simply removed the only FDA-approved finished-drug reference product, which means compounders cannot rely on the "essentially a copy" pathway and must instead qualify under bulk drug substance provisions.

Federal Scheduling: Not a Controlled Substance

The Drug Enforcement Administration (DEA) does not schedule sermorelin. The DEA Controlled Substances Act schedules appear at 21 U.S.C. §812 and its associated regulations. Sermorelin does not appear in Schedules I through V. Prescribing, dispensing, and possessing it therefore carries none of the DEA registration burdens attached to testosterone or human growth hormone (which is explicitly Schedule III under 21 U.S.C. §333(e)).

This is a meaningful distinction. A physician does not need a separate DEA license to prescribe sermorelin. A pharmacy does not need DEA registration to compound and dispense it.

Federal Compounding Law: The 503A and 503B Framework

The two compounding pathways that govern sermorelin's availability nationwide are Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013. The FDA's compounding page summarizes both pathways and their requirements.

Section 503A: Traditional Pharmacy Compounding

A 503A pharmacy may compound sermorelin for an identified individual patient if:

1. A licensed practitioner issues a valid prescription for that specific patient.
2. The pharmacy compounds the preparation in compliance with USP <795> (non-sterile) or USP <797> (sterile) standards, depending on dosage form.
3. The bulk drug substance used is either an FDA-approved active pharmaceutical ingredient or is on the FDA's 503A bulks list.

USP General Chapter <797> governs sterile compounding quality standards. Because sermorelin is typically administered as a subcutaneous injection, USP <797> applies. The pharmacy must maintain a cleanroom, conduct environmental monitoring, and perform beyond-use date testing consistent with those standards.

Section 503B: Outsourcing Facilities

A 503B outsourcing facility may produce sermorelin in larger, non-patient-specific batches for distribution to healthcare facilities and clinics without individual prescriptions at the facility level. FDA registration requirements for outsourcing facilities are outlined in 21 U.S.C. §353b. These facilities undergo FDA inspections on a risk-based schedule and must follow current good manufacturing practice (cGMP) standards, a substantially higher bar than 503A pharmacies.

The Bulk Drug Substance Evaluation and Sermorelin's Current Status

Because sermorelin's brand product is discontinued, it must be nominated for and evaluated on the FDA's 503A bulk drug substance list before 503A pharmacies can legally use it. The FDA maintains a publicly accessible list of nominated 503A bulk drug substances. As of early 2025, sermorelin has been nominated and placed in Category 1 (substances under evaluation) rather than Category 2 (substances that raise safety concerns) or the prohibited list.

Category 1 status means the FDA has not yet published a final decision. Pharmacies operating under enforcement discretion may continue to compound it pending that decision. FDA enforcement policy for Category 1 bulk substances is described in the agency's 2018 draft guidance. If the FDA eventually places sermorelin on the "do not compound" list, 503A pharmacies would have to cease production. That outcome has not occurred as of the publication date of this article.

Michigan State Law: What the State Actually Regulates

Michigan does not have a statute that specifically names sermorelin or restricts its use beyond federal law. The relevant state-level framework comes from three sources.

Michigan Public Health Code (Act 368 of 1978)

Michigan's Public Health Code, Act 368 of 1978, governs controlled substances in Part 72 (MCL 333.7201 to 333.7545). Sermorelin does not appear in Michigan's Schedule I, II, III, IV, or V. This mirrors the federal position. A Michigan pharmacist dispensing sermorelin does not face state-level controlled-substance penalties simply for filling the prescription.

Michigan Board of Pharmacy

The Michigan Board of Pharmacy operates under the Michigan Department of Licensing and Regulatory Affairs (LARA). LARA oversees pharmacy licensing and compliance with the Michigan Pharmacy Practice Act. Any pharmacy dispensing compounded sermorelin to Michigan patients must hold an active Michigan pharmacy license. Out-of-state compounding pharmacies shipping into Michigan are subject to reciprocal licensing requirements: they must register with LARA or qualify as a non-resident pharmacy under Michigan law.

A compounding pharmacy that ships sermorelin to a Michigan patient without proper state registration is operating outside Michigan law regardless of the drug's federal status. Patients should verify that any online pharmacy they use holds a current Michigan non-resident pharmacy license or a NABP (National Association of Boards of Pharmacy) e-Profile accreditation.

Michigan Medical Practice Act

Michigan physicians prescribing sermorelin must do so within the boundaries of the Michigan Medical Practice Act. MCL 333.17001 et seq. Defines the standard of care and scope of prescribing for Michigan-licensed physicians. A prescription for sermorelin must be issued for a legitimate medical purpose based on a valid patient-physician relationship, including an appropriate history, physical examination (or its telehealth equivalent), and documented clinical rationale. Off-label prescribing is legal; prescribing without a clinical basis is not.

Clinical Evidence: Why Physicians Prescribe Sermorelin

Understanding the evidence base helps clarify why prescribing sermorelin falls within accepted medical practice rather than existing in a gray zone.

Growth Hormone Deficiency in Adults

Adult growth hormone deficiency (AGHD) is recognized by the Endocrine Society as a distinct clinical entity. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency recommends GH replacement for confirmed deficiency based on provocative testing. Sermorelin, as a GHRH analog that stimulates endogenous GH release, has been used as an alternative to direct recombinant GH (rhGH) therapy, particularly in patients with intact pituitary function.

The Endocrine Society guideline states: "GH replacement in adults with GHD improves body composition, exercise capacity, skeletal integrity, quality of life, and some cardiovascular risk factors." While this language was written for rhGH, the mechanism of sermorelin (amplifying endogenous pulsatile GH secretion) produces comparable downstream effects on IGF-1 levels.

Published Data on Sermorelin Efficacy

A randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism examined GHRH(1-29) administration in 89 healthy older adults and found statistically significant increases in IGF-1 and sleep-related GH secretion. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. The paper concluded that sermorelin offers a physiologically favorable profile compared to supraphysiologic exogenous GH dosing, as the pituitary's own negative-feedback mechanisms remain intact.

A separate analysis showed that subcutaneous GHRH analog administration over 16 weeks produced a 20 to 30% rise in serum IGF-1 in adults with confirmed AGHD, with a side-effect profile limited primarily to injection-site reactions in roughly 16% of participants. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20-39.

How This Evidence Shapes the Legal Analysis

Prescribers operating in Michigan can point to peer-reviewed literature, Endocrine Society guidance, and a documented diagnostic workup to justify sermorelin prescriptions. This matters because the "legitimate medical purpose" requirement under both federal and Michigan prescribing law is satisfied when a physician can articulate a clinical rationale grounded in evidence. A prescription issued purely for performance enhancement or anti-aging without documented GH-axis testing would be harder to defend under that standard.

How to Get Sermorelin Legally in Michigan

The path to a legal sermorelin prescription in Michigan follows a defined sequence. Each step corresponds to a specific legal requirement.

Step 1: Establish a Valid Patient-Physician Relationship

Michigan telehealth law, updated under MCL 333.16285, permits physicians licensed in Michigan to conduct initial evaluations via synchronous video visits. Michigan's telehealth statute is accessible through the Michigan Legislature site. A synchronous video visit with a complete history, review of symptoms, and ordering of laboratory testing satisfies the patient-physician relationship requirement under Michigan law.

Step 2: Complete the Diagnostic Workup

A clinically defensible prescription requires laboratory confirmation of GH-axis dysfunction. At minimum, this means:

• Fasting serum IGF-1 with age- and sex-adjusted reference ranges
• A GH stimulation test (arginine, glucagon, or macimorelin) if IGF-1 is equivocal
• Metabolic panel, thyroid function, and testosterone/estradiol to rule out confounding deficiencies

The Endocrine Society's 2011 AGHD guideline specifies that a single provocative test with a peak GH <5.0 mcg/L (using immunofunctional assay) is sufficient to confirm severe AGHD in appropriate clinical context. Without this documentation, a prescription may not meet the "legitimate medical purpose" standard.

Step 3: Receive a Prescription and Choose a Compliant Pharmacy

The prescriber issues a written or electronic prescription for sermorelin, typically specifying concentration (e.g., 5 mg/2 mL), injection volume, frequency, and the compounding pharmacy to use. The pharmacy must be either:

• A Michigan-licensed 503A compounding pharmacy in good standing with the Michigan Board of Pharmacy, OR
• A NABP-accredited, FDA-registered 503B outsourcing facility shipping under proper non-resident pharmacy registration in Michigan

NABP's list of accredited pharmacies can be searched at nabp.pharmacy. Patients should request the pharmacy's PCAB (Pharmacy Compounding Accreditation Board) accreditation certificate before filling any prescription.

Step 4: Store and Administer Correctly

Compounded sermorelin acetate is dispensed as a lyophilized powder requiring reconstitution with bacteriostatic water. Reconstituted product must be refrigerated at 2 to 8°C and used within the beyond-use date assigned by the compounding pharmacy under USP <797> guidelines. Typical injection protocols call for subcutaneous administration 5 nights per week before sleep, capitalizing on the nocturnal GH surge pattern. The physiological basis for nocturnal GH pulsatility is reviewed by Van Cauter et al. In Sleep. 2000;23(Suppl 4):S245-252.

Situations Where Sermorelin Use Becomes Illegal in Michigan

Legal status is not binary. Sermorelin is legal when the pathway above is followed. It becomes illegal or legally precarious in specific scenarios.

No Valid Prescription

Dispensing or obtaining sermorelin without a valid prescription violates 21 U.S.C. §353(b), which requires prescription labeling for drugs that are not safe for unsupervised use. The FDA prescription drug requirements are codified in the Federal Food, Drug, and Cosmetic Act at 21 U.S.C. §353. A Michigan resident purchasing sermorelin labeled as "for research use only" from an online chemical vendor is buying an unapproved drug without a prescription, which violates federal law regardless of Michigan's lack of a state-specific ban.

Pharmacy Not Registered in Michigan

An out-of-state compounding pharmacy shipping to Michigan without a Michigan non-resident pharmacy license is violating Michigan pharmacy law. The patient who knowingly uses such a source may have difficulty obtaining legal protections if the product causes harm, and the physician who directed the patient to that pharmacy may face Board action.

Physician Without a Valid Michigan License

Telehealth prescribers must hold either a Michigan medical license or qualify under a specific exemption. Michigan's telehealth prescribing requirements under MCL 333.16285 require licensure in Michigan for ongoing prescribing relationships. A prescriber licensed only in Florida issuing a Michigan patient a sermorelin prescription via telehealth without Michigan licensure is operating outside legal bounds.

Comparing Sermorelin to Other Peptides Under Federal Scrutiny

The FDA's approach to compounded peptides has not been uniform. Understanding where sermorelin sits relative to other peptides in regulatory risk helps Michigan patients and clinicians assess stability of access.

Peptides removed from compounding availability include BPC-157, TB-500 (thymosin beta-4), and CJC-1295, which the FDA placed on the Category 2 list in 2023, effectively prohibiting their compounding under 503A. The FDA's updated 503A bulk drug substance Category 2 list is published on the FDA compounding page. Ipamorelin and tesamorelin occupy different regulatory positions: tesamorelin (Egrifta) retains an approved brand, while ipamorelin sits in a similar Category 1 evaluation as sermorelin.

Sermorelin's longer clinical history, its prior FDA approval as Geref, and the published evidence supporting its use in GH-axis testing all position it more favorably than newer research peptides with no prior approval history. The FDA's Category 1 evaluation could produce a negative outcome. Clinicians and patients should monitor the FDA's bulk substance list for updates at least quarterly.

The FDA has stated in its guidance: "FDA intends to take action against the compounding of a bulk drug substance if the substance is on the list of bulk drug substances that may not be used in compounding." Sermorelin is not on that list as of January 2025.

Dosing Reference for Clinicians Prescribing Sermorelin

Typical prescribed regimens used in clinical practice include:

• Low-dose: 100 to 200 mcg subcutaneous injection, 5 nights/week
• Standard dose: 200 to 300 mcg subcutaneous injection, 5 nights/week
• Monitoring interval: Serum IGF-1 at 8 to 12 weeks after initiation, then every 6 months
• Target IGF-1 range: Age- and sex-adjusted mid-normal range per the laboratory's reference interval

Endocrine Society guidance recommends titrating GH-axis therapy to achieve IGF-1 within the age-adjusted normal range, not the upper quartile. The same titration principle applies when using GHRH analogs such as sermorelin.

Injection timing before sleep is not arbitrary. A study published in the Journal of Clinical Endocrinology and Metabolism showed that 70% of daily GH secretion in adults occurs during slow-wave sleep, with peak pulses between 11 p.m. And 1 a.m. Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA. 2000;284(7):861-868. Administering sermorelin 30 to 60 minutes before sleep amplifies this natural secretory window.